Therame

TheraMe! a medtech spinoff from EPFL is at the forefront of advancing cancer treatment. TheraMe! AG was founded in 2023 with a successful seed round. Our journey is rooted in over a decade of academic research conducted in collaboration with a multinational consortium. This solid foundation drives our commitment to revolutionize cancer therapy through state-of-the-art microfluidic technology. Internationally renowned experts and university professors in the fields of microfluidics, bioinformatics and clinical oncology work together at TheraMe, having a single goal in mind: Identifying the very best treatment option for any cancer patient, at any stage of the disease. Our mission to redefine cancer care. At TheraMe, we're not just advancing medicine, we're transforming lives.